Subscribe to our Email Alerts

ACCENT Trial Update


Amplia has today released an update on the ACCENT trial in pancreatic cancer. 

Following the completion of the Phase 1b portion of the trial in November 2023, a safe and well-tolerated dose of 400 mg narmafotinib once-a-day was identified. Response rates from the Phase 1b portion of the trial continue to be substantially better in terms of clinical response and duration on trial, when compared to treatment with chemotherapy alone. 

Recruitment for the Phase 2a stage of the trial is progressing well, with 11 patients currently in the Phase 2a cohort – 7 patients across Australian trial sites, and a further 4 pancreatic cancer patients in Korea. 

The Phase 2a trial will initially enrol 26 patients and an interim analysis of efficacy will be conducted around Q3 2024.   

Amplia CEO and MD, Dr Chris Burns, commented:  

“The clinical responses we are seeing in patients is very promising and the duration on trial, given the aggressiveness of the disease in these patients, is also extremely encouraging.” 

Click here to read the ASX release.